Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer

Christa Babst a,1, Thomas Amiela,1, Tobias Maurer b, Sophie Knipper b, Lukas Lunger a, Robert Tauber a, Margitta Retz a, Kathleen Herkommer a, Matthias Eiber a, Gunhild von Amsberg b, Markus Graefen b, Juergen Gschwend a, Thomas Steuber b, Matthias Heck a,*

a Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany
b Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Received 30 May 2020; received in revised form 25 October 2020; accepted 20 January 2021
Available online 22 April 2021

Abstract  Objective: Cytoreductive radical prostatectomy (cRP) has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer (mHSPC) to prevent local complications and potentially improve oncological outcomes. In this study, we examined the feasibility of a multimodal concept with primary chemohormonal therapy followed by cRP and analyzed prostate size reduction under systemic treatment, postoperative complication rates, as well as early postoperative continence.

Methods: In this retrospective study, 38 patients with mHSPC underwent cRP after primary chemohormonal therapy (3-monthly luteinising hormone-releasing hormone-analogue + six cycles 3-weekly docetaxel 75 mg/m²) at two centers between September 2015 and December 2018.

Results: Overall, 10 (26%) patients had high volume and 28 (74%) patients had low volume disease at diagnosis, according to CHAARTED definition. Median prostate-specific antigen (PSA) decreased from 65 ng/mL (interquartile range [IQR] 35.0–124.5 ng/mL) pre-chemotherapy to 1 ng/mL (IQR 0.3–1.7 ng/mL) post-chemotherapy. Prostate gland volume was significantly reduced by a median of 50% (IQR 29%–56%) under chemohormonal therapy (p < 0.003). Postoperative histopathology showed seminal vesicle invasion in 33 (87%) patients and negative surgical margins in 17 (45%) patients. Severe complications (Grade 3 according to Clavien-Dindo) were observed in 4 (11%) patients within 30 days. Continence was reached in 87% of patients after 1

* Corresponding author.

E-mail address: matthias.heck@tum.de (M. Heck).

Peer review under responsibility of Tongji University.

1 These two authors contributed equally to this work.

https://doi.org/10.1016/j.ajur.2021.04.003

2214-3882/© 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

About 10% of patients diagnosed with prostate cancer present with metastatic disease at diagnosis or develop metastases after primary local therapy, so-called metastatic hormone-sensitive prostate cancer (mHSPC) [1]. Chemohormonal therapy with androgen-deprivation therapy (ADT) and docetaxel was the first systemic treatment combination to show improved overall survival in this setting (CHAARTED and STAMPEDE trial) [2,3]. However, it has been shown that lethal prostate cancer cells persist in the primary tumor of the prostate despite aggressive treatment with chemohormonal therapy [4]. Moreover, it has been reported that new metastases will develop from both, metastases as well as from the primary tumor [5]. Therefore, it has been hypothesized that patients may benefit from local treatment of the prostate even in a metastatic stage of the disease. In fact, the STAMPEDE trial [3] recently reported an overall survival benefit in a subgroup of patients with mHSPC undergoing local treatment of the prostate with radiation therapy. In the total patient cohort overall survival did not differ between the radiation arm and the control arm. However, in a preplanned subgroup analysis the authors stratified patients according to tumor volume. While patients with low tumor volume achieved longer overall survival, patients with high tumor volume (CHAARTED trial definition: Presence of visceral metastasis or presence of four or more bone metastases with at least one metastasis being localized outside of the pelvis or vertebral column) did not benefit from local radiation. However, local radiation of the prostate did not prevent local symptomatic complications resulting from prostate cancer progression of the primary tumor.

Even though data on randomized-controlled trials for cytoreductive radical prostatectomy (cRP) in primary mHSPC are not available yet, retrospective series reported that cRP leads to prolonged cancer-specific survival [6], as well as overall survival [7,8] and prevents local complications [9–11].

2. Methods

Based on these data, we pursued in a series of 38 patients, a multimodal concept offering cRP to patients with primary mHSPC who responded well to primary chemohormonal therapy. In this retrospective analysis, we aimed to demonstrate the feasibility of cRP after chemohormonal therapy with prostate size reduction under chemohormonal therapy, postoperative complication rates according to Clavien-Dindo [12], as well as early postoperative continence assessing the number of pads used per day.

All patients presented with newly diagnosed mHSPC and received primary chemohormonal therapy followed by cRP (35 open surgeries and three robotic) between September 2015 and December 2018 at two centers (Department of Urology at Technical University of Munich [n = 26] and Martini Klinik in Hamburg [n = 12], Germany). The initial diagnosis of mHSPC was confirmed by transrectal biopsy of the prostate gland. All patients received chemohormonal therapy (3-monthly luteinising hormone-releasing hormone-analogue continuously + six cycles 3-weekly docetaxel 75 mg/m²) [3]. Subsequently, cRP was offered to patients at the discretion of the treating urologist based on prostate-specific antigen (PSA) reduction >50% and at least partial response on imaging according to Response Evaluation Criteria in Solid Tumors. Staging procedures at initial diagnosis and response assessment after chemohormonal therapy included computed tomography (CT) and bone scan or prostate specific-membrane antigen-ligand positron emission tomography (PSMA PET).

Castration-resistance was defined as rise in PSA resulting in a 50% increase over the nadir and PSA >2 ng/mL under systemic therapy with testosterone-levels <50 ng/dL according to current European Association of Urology guidelines [13].

Time to castration-resistance and associated 95% confidence intervals (CIs) with log-rank statistics were calculated with the use of the Kaplan-Meier method. Data analyses were performed using SPSS version 25.0 (IBM Corp, Armonk, NY, USA).

3. Results

Patient characteristics of a total of 38 included patients are shown in Table 1. At initial diagnosis 28 (74%) patients presented with low volume disease and 10 (26%) patients with high volume disease. The median time from the end of chemotherapy to surgery was 61 days (interquartile range [IQR] 47–82 days). Chemohormonal therapy
led to a significant median prostate volume reduction of 50% (IQR 29%–56%) from a median of 50 mL pre-chemotherapy to 25 mL post-chemotherapy (p=0.003). Median PSA decreased from 65.0 (35.0–124.5) ng/mL pre-chemotherapy to 1 (0.3–1.7) ng/mL post-chemotherapy.

Table 1. Descriptive characteristics of 38 patients treated with cytoreductive radical prostatectomy after chemohormonal therapy.

| Characteristic                                      | Value                        |
|----------------------------------------------------|------------------------------|
| Age, median (IQR), year                            | 57 (54–64)                   |
| Number of patients, n (%)                           |                              |
| ≥65 years                                          | 9 (23)                       |
| <65 years                                          | 29 (77)                      |
| ASA score, median (IQR)                            | 2 (2–2)                      |
| PSA, median (IQR), ng/mL                           |                              |
| At diagnosis                                       | 65 (35.0–124.5)              |
| Pre-surgery                                        | 1.0 (0.3–1.7)                |
| Gleason score, n                                   |                              |
| 6                                                   | 1                            |
| 7a                                                  | 2                            |
| 7b                                                  | 2                            |
| 8                                                   | 9                            |
| 9                                                   | 21                           |
| 10                                                  | 3                            |
| Median (IQR)                                       | 9 (8–9)                      |
| CHAARTED criteria, n (%)                            |                              |
| Low volume disease                                 | 28 (74)                      |
| High volume disease                                | 10 (26)                      |
| Metastases status at diagnosis, n (%)               |                              |
| Lymph node                                         | 33 (87)                      |
| Bone                                               | 23 (61)                      |
| Visceral                                           | 2 (5)                        |
| Time from diagnosis to chemotherapy, median (IQR), day | 53 (32–74)                   |
| Time from diagnosis to surgery, median (IQR), day   | 250 (222–281)                |
| Time from end of chemotherapy to surgery, median (IQR), day | 61 (47–82)                  |
| Prostate volume, median (IQR), mL                  |                              |
| Pre-docetaxel                                       | 50 (35–64)                   |
| Pre-surgery                                        | 25 (15–31)                   |
| Prostate volume reduction, median (IQR), mL         | 25 (10–35)                   |
| Prostate volume reduction, median (IQR), %          | 50 (29–56)                   |
| Hemoglobin, median (IQR), g/dL                      |                              |
| Pre-surgery                                        | 13.7 (13.0–14.1)             |
| Post-surgery (Day 1 after surgery)                 | 10.7 (10.2–12.1)             |
| Hemoglobin loss, median (IQR), g/dL                 | 2.9 (1.9–3.4)                |
| Operation time, median (IQR), min                   | 196 (157–233)                |
| Hospital length of stay, median (IQR), day          | 9 (6–10)                     |
| Postoperative T stage, n (%)                        |                              |
| pT2c                                               | 2 (5)                        |
| pT3a                                               | 3 (8)                        |
| pT3b                                               | 33 (87)                      |
| Postoperative N stage, n (%)                        |                              |
| pN0                                                | 4 (11)                       |
| pN1                                                | 34 (89)                      |
| Lymph nodes removed, median (IQR), n                | 18.5 (12–24)                 |
| Positive lymph nodes, median (IQR), n               | 3 (1–6)                      |
| Margin status, n (%)                                |                              |
| R0                                                 | 17 (45)                      |
| R1                                                 | 21 (55)                      |

IQR, interquartile range; ASA, American Society of Anesthesiologists; PSA, prostate-specific antigen.

Median time to castration-resistance from begin of chemohormonal therapy was 41.1 months (95% CI not available [NA]) (Fig. 1). Median follow-up time after surgery was 22.6 months (range 5.7–48.6 months). During this time, 14 of 38 patients (37%) developed a rising PSA above 2 ng/mL postoperatively.
Median time from cRP to castrations-resistance was 35.9 months (95% CI NA) (Fig. 2). Preoperative PSA-nadir ≤1 ng/mL versus >1 ng/mL was not associated with time to castration-resistance (p=0.9). However, postoperative PSA-nadir was a significant predictor of time to castration-resistance after cRP. In patients with PSA-nadir values ≤1 ng/mL after cRP, the time to castration-resistance was significantly longer than that in patients with PSA-nadir values >1 ng/mL (95% CI 0.0–12.3; p<0.0001) (Fig. 3).

After cRP, histopathologic work-up showed seminal vesicle invasion in 33 (87%) patients; out of those 27 (71%) men had bilateral infiltration, while a negative surgical margin could be achieved in 17 (45%) patients. Overall 37 of 38 (97%) patients had histopathologic positive lymph nodes.

Within 30 days postoperatively most patients (33 [87%]) did not develop any complications. One patient developed an asymptomatic lymphocele (Grade I according to Clavien-Dindo). Severe complications (Grade 3 according to Clavien-Dindo) were observed in 4 (11%) patients within 30 days. Two (5%) patients with lymphoceles required percutaneous drainage, out of which 1 (3%) patient received a laparoscopic marsupialization. Moreover, 1 (3%) patient needed a percutaneous nephrostomy with antegrade ureteral stent insertion. The stent could be removed later without further urinary obstruction.

Looking at the first year postoperatively, 29 (76%) patients did not develop any complications. Severe complications (Grade 3) were observed in 7 (18%) patients. Two more patients had to be treated with laparoscopic marsupialization for lymphoceles (3 months and 4 months after surgery) and one patient suffered from a stricture of the vesico-urethral anastomosis, which was treated by internal urethrotomy, 11 months after surgery. Grade ≥4 complications were not observed. As a limitation, in four patients we could only collect follow-up data up to 6 months after surgery.

Data on postoperative continence after 1, 6 and 12 months were available for 31 (82%), 25 (66%) and 26 (68%) patients, respectively. Continence, defined as usage of up to one pad for safety, was reached in 27 of 31 (87%) patients after 1 month, 23 of 25 (92%) patients after 6 months, and 23 of 26 (88%) after 1 year (Table 2).

4. Discussion

To our knowledge, this is the first study investigating a multimodal concept with chemohormonal therapy followed

| Pad use | Postoperative continence after 1 month | Postoperative continence after 6 months | Postoperative continence after 12 months |
|---------|--------------------------------------|----------------------------------------|----------------------------------------|
| 0 pad   | 2 (6)                                | 15 (60)                                | 18 (69)                                |
| 1 pad   | 25 (81)                               | 8 (32)                                 | 5 (19)                                 |
| (for security) |                                  |                                        |                                        |
| 1 wet pad | 1 (3)                                | 1 (4)                                  | 1 (4)                                  |
| (mild incontinence) |                              |                                        |                                        |
| 2 wet pads | 3 (10)                               | 1 (4)                                  | 2 (8)                                  |
| (moderate incontinence) |                         |                                        |                                        |
| ≥3 pads | 0                                    | 0                                      | 0                                      |
| (severe incontinence) |                                 |                                        |                                        |

Table 2 Continece and pad use.

a The other seven were unknown.
b The other 13 were unknown.
c The other 12 were unknown.
by cRP in mHSPC. In our study, systemic therapy led to a significant prostate volume reduction potentially alleviating subsequent surgery with a low rate of postoperative complications and good early continence. The observed complication and continence rates are comparable to those observed in patients undergoing radical prostatectomy for localized prostate cancer [14,15]. This is demonstrated in data with a large contemporary prostatectomy series with curative intention from our institution, where we analyzed the complication rate 3 months postoperatively. It showed similar data with 20.6% at least having one Clavien-Dindo complication; out of them, 7% had severe complications [14]. Also the current data concerning the continence rate are similar to a recently published prostatectomy series of high risk and very high-risk prostate cancer patients from our institution. Continence rates after standard radical prostatectomy were 69% at 3 months and 82% after 1 year [16]. Thus, sequential therapy with downsizing of the prostate and the tumor by previous systemic therapy may be beneficial.

A multimodal concept with primary systemic chemo-hormonal therapy followed by local therapy is also described in the randomized phase-III trial STAMPEDE [3]. Here, a subgroup of 183 (18%) patients received chemo-hormonal therapy followed by radiation of the prostate. In this trial docetaxel was permitted in addition to ADT after its approval in the UK. The study showed an overall survival benefit in patients with low volume disease. However, prevention of local complications could not be shown for local radiation therapy.

In contrast, a survival benefit, as well as prevention of local complications has been shown for the concept of cRP, although only in retrospective studies and without investigating multimodal treatment strategies [6–8,10]. However, prospective randomized-controlled trials are still ongoing and therefore, have to be awaited to validate the therapeutic role of cRP in mHSPC. Moreover, it’s unclear whether patients undergoing cRP should be selected based on low tumor volume as indicated for radiation therapy in the STAMPEDE trial.

In the current series of multimodal treatment with chemo-hormonal therapy followed by cRP, about one quarter of patients had high volume and three quarters had low volume disease. While the CHAARTED trial only showed a survival benefit from chemo-hormonal therapy for patients with high volume disease [17], latest data from the STAMPEDE trial suggested that chemo-hormonal therapy improved overall survival in newly diagnosed mHSPC regardless of tumor volume [18]. The difference may arise from different inclusion criteria in both trials with mainly including de novo metastatic disease in the STAMPEDE trial and in contrast a high rate of patients with tumor recurrence following local therapy in the CHAARTED trial, which may represent biologically different tumors and were unequally distributed between patients with high and low volume disease [19]. Thus, our approach offering primary chemo-hormonal therapy in de novo metastatic HSPC independent of tumor volume is supported by the STAMPEDE trial.

Meanwhile, several other systemic therapies have shown survival benefits in mHSPC including the androgen-biosynthesis-inhibitor abiraterone (LATITUDE and STAMPEDE trial) [3,20], as well as the antiandrogens enzalutamide (ARCHES and ENZAMET trial) [21,22] and apalutamide (TITAN trial) [23], which could also be combined with local therapy in a multimodal concept followed by local treatment.

Limitations of our case series are retrospective design, small number of patients, and missing long-term oncologic outcome.

5. Conclusion

In summary, cRP after chemohormonal therapy seems feasible in selected patients with no major complications and good postoperative continence rates. Future trials will have to clarify the oncological benefit of this concept.

Author contributions

Study concept and design: Matthias Heck.
Data acquisition: Christa Babst, Thomas Amiel, Sophie Knipper, Kathleen Herkommer.
Data analysis: Christa Babst, Lukas Lunger, Matthias Heck.
Drafting of manuscript: Christa Babst, Thomas Amiel, Matthias Heck.
Critical revision of the manuscript: Tobias Maurer, Sophie Knipper, Lukas Lunger, Robert Tauber, Margitta Retz, Kathleen Herkommer, Matthias Eiber, Gunhild von Amsberg, Markus Graefen, Juergen Gschwend, Thomas Steuber.

Conflicts of interest

The authors declare no conflict of interest.

References

[1] Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.
[2] Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46.
[3] James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–77.
[4] Tzelepi V, Efstathiou E, Wen S, Troncoso P, Kariou M, Pettaway CA, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011;29:2574–81.
[5] Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353–6.
[6] Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058–66.
[7] Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: Data from the Munich Cancer Registry. Eur Urol 2014;66:602–3.
[8] Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol 2017;72:118–24.

[9] Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 2017;3:646–9.

[10] Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low-volume skeletal metastases: Results of a feasibility and case-control study. J Urol 2015;193:832–8.

[11] Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol 2018:46–53.

[12] Mitropoulos D, Artibani W, Biyani CS, Bjerggaard Jensen J, Roupré M, Truss M. Validation of the Clavien-Dindo grading system in urology by the European Association of Urology guidelines ad hoc panel. Eur Urol Focus 2018;4:608–13.

[13] Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al; Members of the EAU–ESTRO–ESUR–SIOG prostate cancer guidelines panel. EAU–ESTRO–ESUR–SIOG Guidelines on Prostate Cancer. [Accessed 15 August 2020]. https://uroweb.org/guideline/prostate-cancer/.

[14] Pompe RS, Beyer B, Haese A, Preisser F, Michl U, Steuber T, et al. Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU Int 2018;122:801–7.

[15] Michl U, Tennstedt P, Feldmeier L, Mandel P, Oh SJ, Ahyai S, et al. Nerve-sparing surgery technique, not the preservation of the neurovascular bundles, leads to improved long-term continence rates after radical prostatectomy. Eur Urol 2016;69:584–9.

[16] Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, et al. Oncological and functional outcome after radical prostatectomy for high or very high-risk prostate cancer: European validation of the current NCCN® guideline. J Urol 2017;198:354–61.

[17] Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–7.

[18] Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann Oncol 2019;30:1992–2003.

[19] Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, et al. Burden of metastatic castrate naïve prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 2018;73:847–55.

[20] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–60.

[21] Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azaad A, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37:2974–86.

[22] Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121–31.

[23] Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13–24.